Passi Janne, MD, PhD

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

October 27th 2025

Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025.